# Marginal zone lymphoma

The EU has approved 1 indication of 1 drug in marginal zone lymphoma. None of them needs a biomarker result.

## Approved indications

### No biomarker required

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Zanubrutinib](https://oncolabels.com/drugs/zanubrutinib) (Brukinsa) | None | Monotherapy | 2nd line | After at least one prior anti-CD20-based therapy |

## Label wording

- **Zanubrutinib** (Brukinsa), Marginal zone lymphoma, 2nd line: “BRUKINSA as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/marginal-zone-lymphoma